Blog

Jul 15, 2024, 13:21

Talha Badar: CRh as a Palliative Endpoint for Treatment of Acute Myeloid Leukemia

Talha Badar shared on X:

“Complete remission with partial hematological recovery as a palliative endpoint for treatment of acute myeloid leukemia

Pooled analysis of IDH1/2i and FLT3i in clinical trails, suggest CRh meaningful endpoint in improving outcome with non-myelosuppressive therapies.

Authors: Robert Q. Le, Donna Przepiorka, Haiyan Chen, Yuan Li Shen, E. Dianne Pulte, Kelly Norsworthy, Marc R. Theoret, R. Angelo De Claro.”

Talha Badar

Source: Talha Badar/X

Dr. Talha Badar, MD, is a specialist in Hematology Oncology based in Mayo Clinic, Jacksonville, Florida. His primary areas of expertise include Leukemia, particularly Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Acute Lymphoblastic Leukemia (ALL), and Bone Marrow Transplantation. Over his career, he has actively contributed to clinical research and clinical trials.

Acute Myeloid Leukemia cancer Donna Przepiorka E. Dianne Pulte Haiyan Chen Kelly Norsworthy Marc R. Theoret OncoDaily Oncology R. Angelo De Claro Robert Q. Le Talha Badar Yuan Li Shen

Oncologist Near Me - Vivek Subbiah: Pionner of Precision Oncology

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success

One Hand Gives, Another Takes? Trump, Musk, Congress and Childhood Cancer Research Funding

Special Coverage